engleski

In rats with superior mesenteric artery-occlusion pentadecapeptide BPC 157 counteracts GI tract lesions, portal and caval hypertension and aortal hypotension, activates bypassing pathway, and acts in relation with no-system involvement

We focused on the 15 min superior mesenteric artery (SMA) occlusion and stable gastric pentadecapeptide BPC 157 therapy, and NO-system involvement with L-NAME and Larginine application. Recently, along with the bypassing pathway in rats with inferior caval vein occlusion, which rapidly appears after BPC 157 application (Vascul Pharmacol 2018 ; 106:54-66), superior mesenteric vein (SMV) venography bellow occlusion in rats with 15 min SMV-occlusion shows rapid presentation of the bypassing pathway SMV -middle colic vein (MCV)-inferior mesenteric vein (IMV)- SMV-portal vein (PV), as a clue that BPC 157 medication may consistently counteract huge SMV, PV, and inferior caval vein (ICV) hypertension, mild aortic hypotension, peaked P waves and tachycardia, marked venous thrombosis, and oxidative stress (Gastroenterology, Vol. 156, Issue 6, S-707–S- 708). Methods. Medication (/kg) (BPC 157 (10 µg, 10 ng), L-NAME (5 mg), and/or L-arginine (100 mg) or saline (5 ml) (controls)) was applied as an abdominal bath immediately after SMA occlusion. Results. 15 min SMA occlusion produced marked lesions in the stomach, duodenum, jejunum, cecum and colon, which BPC 157 counteracts. At the end of the 15 min, rats with SMA occlusion exhibit huge PV and ICV hypertension, severe aortic hypotension (controls, means±SD mmHg, 47±3 (PV), 32±3 (ICV), 70±3 (abdominal aorta)), which were markedly opposed (BPC 157 rats) (17±4 (µg), 15±4 (ng) (PV), 11±3 (µg), 10±4 (ng) (ICV), 97±3(µg), 95±4 (ng) (abdominal aorta)). Accordingly, superior mesenteric vessels thrombosis was markedly attenuated in both vein and artery (SMV 0.0301±0.001 g (controls) vs. 0.0095±0.0009 (µg), 0.0099±0.0007 (ng) and SMA 0.0238±0.001 g (controls) vs. 0.0072±0.0009 (µg), 0.0080±0.0008 (ng)). Angiography (Shimatzu, DSA C Vision at 5 min ligation-time)and USB microscope camera assessment show bypassing pathway inferior mesenteric artery (IMA)-arch of Riolan (AoR)-SMA, along with inferior anterior pancreaticoduodenal artery (IAPDA) presentation to replete original SMA flow (Fig. 1, Fig. 2). In cecum of rats underwent SMA-ligation that received BPC 157 we evidenced TBARS values corresponding to normal healthy values, and thereby counteracted oxidative stress increased values (Fig. 1). Given alone L-NAME and L-arginine have opposite effect on the stomach, duodenum, jejunum, cecum and colon lesions. L- arginine counteracted lesions, L-NAME aggravated stomach lesions. Given together (L- NAME+L-arginine), L-NAME could not completely antagonize L-arginine beneficial effect. BPC 157 given with NO-agent(s) maintainedits original beneficial effect. In conclusion, these beneficial effects in rats with SMA-occlusion indicate that pentadecapeptide BPC 157 counteracts GI tract lesions, portal and caval hypertension and aortal hypotension, activates bypassing pathway, and acts in relation with NOsystem involvement.

superior mesenteric artery ; occlusion ; BPC 157

nije evidentirano